Current Position:

• Holder of the Chair of Clinical and Experimental Diabetology, Department of Internal Medicine IV, University Hospital of Tübingen, Germany

• Head of the Dept. of Pathophysiology of Prediabetes at the Institute of Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich 

Selected Employment:

2000-2003 Fellow at the NIH, NIDDK, Phoenix, USA

2003-2007 Senior Scientist, Univ. of Tübingen, Germany

2007-2011 Assistant Professor 

2011-     Full Professor; Heisenberg-Professorship for Clinical and Experimental Diabetology 

2018-2020 Visiting Professor, Harvard Medical School, Boston, USA

Selected current Scientific Positions:

• International Advisory Board Member of The Lancet Diabetes & Endocrinology

• Senior Associate Editor of Diabetes 

Research Interests:

• Pathophysiology of prediabetes and type 2 diabetes

• Metabolically healthy and unhealthy obesity and normal weight (First detailed phenotypic characterization of metabolically healthy obesity in 2008)

• Causes, cardiometabolic consequences and treatment of steatotic liver disease (First introduction of the term hepatokine in 2008)

Selected Scientific Publications:

1. Stefan N et al., Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008

2. Stefan N, Schick F, Häring HU. Sex hormone-binding globulin and risk of type 2 diabetes. N. Engl. J. Med. 2009

3. Stefan N, Häring HU. Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med. 2013  

4. Stefan N et al., Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014

5. Stefan N, Schick F, Häring HU. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metab. 2017

6. Eigentler T, … Stefan N. Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade. Ann Intern Med. 2020 

7. Stefan N et al., The role of hepatokines in NAFLD. Cell Metab. 2023

8. Stefan N, Yki-Järvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2024